Prove2 study: Treatment of chronic hepatitis C with telaprevir (TVR)in combination with peginterferon-alfa-2a with or without ribavirin, interim analysis results

被引:0
|
作者
Hezode, Christophe
Ferenci, Peter
Dusheiko, Geoffrey M.
Tran, Albert
Grange, Jean-Didier
Mathurin, Philippe
Schmidt, Wolfgang E.
Diepolder, Helmut
Marcellin, Patrick
Wedemeyer, Heiner
Forestier, Nicole
Mangels, Wendy
Gharakhanian, Shahin
Kauffman, Robert S.
Alam, John
Pawlotsky, Jean-Michel
Zeuzem, Stefan
机构
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
引用
收藏
页码:A755 / A755
页数:1
相关论文
共 50 条
  • [41] Response-guided Telaprevir Combination Treatment in Genotype 1 Chronic Hepatitis C Patients who had Prior Relapse to Peginterferon Alfa-2a/Ribavirin
    Muir, Andrew
    Adiwijaya, Bambang
    Poordad, Fred
    Gritz, Linda
    Bengtsson, Leif
    Luo, Don
    Picchio, Gaston
    Kauffman, Robert
    Adda, Nathalie
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S114 - S115
  • [42] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C - Reply
    Fried, MW
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (03): : 260 - 260
  • [43] Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil
    Barros F.M.R.
    Cheinquer H.
    Tsuchiya C.T.
    Santos E.A.V.
    Cost Effectiveness and Resource Allocation, 11 (1)
  • [44] Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
    McHutchison, John G.
    Lawitz, Eric J.
    Shiffman, Mitchell L.
    Muir, Andrew J.
    Galler, Greg W.
    McCone, Jonathan
    Nyberg, Lisa M.
    Lee, William M.
    Ghalib, Reem H.
    Schiff, Eugene R.
    Galati, Joseph S.
    Bacon, Bruce R.
    Davis, Mitchell N.
    Mukhopadhyay, Pabak
    Koury, Kenneth
    Noviello, Stephanie
    Pedicone, Lisa D.
    Brass, Clifford A.
    Albrecht, Janice K.
    Sulkowski, Mark S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (06): : 580 - 593
  • [45] Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden
    Bernfort, Lars
    Sennfalt, Karin
    Reichard, Olle
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2006, 38 (6-7) : 497 - 505
  • [46] Treatment persistence in and cost of therapy for patients with chronic hepatitis C: Peginterferon alfa-2a plus ribavirin versus peginterferon alfa-2b plus ribavirin
    Brixner, Diana I.
    Ye, Xin
    Chu, Teng-Chiao
    Blumentals, William A.
    Hassanein, Tarek I.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2009, 66 (24) : 2171 - 2178
  • [47] Treatment of chronic hepatitis C with peginterferon alfa-2a (40KD) and ribavirin in patients with or without drug use
    Zehnter, Elmar
    Mauss, Stefan
    John, Christine
    Heyne, Renate
    Moeller, Bernd
    Lutz, Thomas
    Bokemeyer, Bernd
    Kihn, Robert
    Moog, Gero
    Vornkahl, Heike
    Alshuth, Ulrich
    Hueppe, Dietrich
    GASTROENTEROLOGY, 2006, 130 (04) : A840 - A840
  • [49] Swiss Multicenter Study Evaluating the Efficacy, Feasibility and Safety of Peginterferon-Alfa-2a and Ribavirin in Patients with Chronic Hepatitis C in Official Opiate Substitution Programs
    Fried, Ronald
    Monnat, Martine
    Seidenberg, Andre
    Oppliger, Robert
    Schmid, Patrick
    Herold, Markus
    Isler, Marc
    Broers, Barbara
    Koelliker, Christoph
    Schoenbucher, Peter
    Frei, Markus
    Huber, Milo
    DIGESTION, 2008, 78 (2-3) : 123 - 130
  • [50] Impact of Asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C
    Missiha, Sharif
    Heathcote, Jenny
    Arenovich, Tamara
    Khan, Kamran
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 (10): : 2181 - 2188